The current role of calcineurin inhibitors in posttransplant immunosuppression?

American Journal of Transplantation

Volumn 6, Issue 12, 2006, Pages 2827-2829

  Matas, A J ^a   Kandaswamy, R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Calcineurin inhibitors; Immunosuppression; Kidney transplant; Nephrotoxicity

Indexed keywords

CALCINEURIN INHIBITOR;

CONTROLLED STUDY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY GRAFT; NEPHROTOXICITY; PRIORITY JOURNAL; PUBLICATION; SHORT SURVEY; SURVIVAL RATE;

CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TRANSPLANTATION IMMUNOLOGY;

EID: 33751196089     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01568.x     Document Type: Short Survey

References (28)

1. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M. Cyclosporine- associated chronic nephropathy. N Engl J Med 1984; 311: 699-705.
2. Sibley RK, Rynasiewicz J, Ferguson RM, Fryd D, Sutherland DE, Simmons RL et al. Morphology of cyclosporine nephrotoxicity and acute rejection in patients immunosuppressed with cyclosporine and prednisone. Surgery 1983; 94: 225-234.
3. Sommer BG, Innes JT, Whitehurst RM, Sharma HM, Ferguson RM. Cyclosporine-associated renal arteriopathy resulting in loss of allograft function. Am J Surg 1985; 149: 756-764.
4. Ryffel B, Mihatsch MJ. Cyclosporine nephrotoxicity. Toxicol Pathol 1986; 14: 73-82.
5. Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite amarked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378-383.
6. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786.
7. Oberbauer R, Kreis H, Johnson RW, Mota A, Claesson K, Ruiz JC et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364-370.
8. Kreis H, Oberbauer R, Campistol JM, Mathew T, Daloze P, Schene FP et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809-817.
9. Oberbauer R, Segoloni G, Campistol JM, Kreis H, Mota A, Lawen J et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005; 18: 22-28.
10. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 9: 2326-2333.
11. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RDM, Chapman JR. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 461-468.
12. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RDM. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557-565.
13. Nankivell BJ, Borrows RJ, Fund CL, O'Connell PJ, Allen RD, Chapman JR. National history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242-249.
14. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026.
15. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M et al. Beneficial effects of treatment of early subclinical rejection: A randomized study. J Am Soc Nephrol 1998; 9: 2129-2134.
16. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464-2472.
17. Humar A, Hassoun A, Kandaswamy R, Payne WD, Sutherland DE, Matas AJ. Immunologic factors: The major risk for decreased long-term renal allograft survival. Transplantation 1999; 68: 1842-1846.
18. Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
19. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
20. Abramowicz D, del Carmen Rial M, Vitko S, del Castillo D, Manas D, Lao M et al. On behalf of the Cyclosporine Withdrawal Study Group. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: Results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234-2240.
21. Meier-Kriesche H-U, Hricik DE. Are we ready to give up on calcineurin inhibitors? Am J Transplant 2006; 6: 445-446.
22. Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Saric E et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 1706-1710.
23. Weir MR, Ward MT, Blahut SA, Klassen DK, Cangro CB, Bartlett ST et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
24. Egidi MF, Cowan PA, Naseer A, Gaber AO. Conversion to sirolimus in solid organ transplantation: a single-center experience. Transplant Proc 2003; 35: 131S-137S.
25. Peddi VR, Jensik S, Pescovitz M, Pirsch J, Adler SH, Thistlethwaite JR et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19: 130-136.
26. Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869-1875.
27. Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24: 379-386.
28. Land W, Vincenti F. Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation. Transplantation 2005; 80: S221-S234.